Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Continues Restructuring: Lays Off 30, Brings on New CBO, Board Member

NEW YORK, April 28 - In the latest phase of a restructuring plan that began in July 2002, Aclara today said it has let go an additional 30 employees, hired a new chief business officer, and appointed a new member to its board of directors.


Aclara said it carried out these steps with the goal of further increasing its focus on commercializing its eTag assay system - a strategy the company began implementing in July, when it first announced its restructuring plans and the elimination of 50 staffers.


Today, Aclara said it would eliminate an additional 30 positions in executive management, administration, marketing, and basic research, bringing its total headcount to 65.


"We believe these actions, while certainly difficult, allow us to focus on our most important priority, the commercialization and rapid adoption of eTag assays," said Thomas Klopack, Aclara's CEO, in a statement.


Michael Dunn, formerly executive VP of business development at Aurora Biosciences, will join the company to fill the new position of CBO, where he will be responsible for business development, sales, and marketing.


In addition, Affinium Pharmaceuticals CEO John Mendlein has been appointed to Aclara's board of directors.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.